BRCA Status Dictates Wnt Responsiveness in Epithelial Ovarian Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• BRCA1/BRCA2 mutations increase ovarian cancer risk.
• Clinical outcomes differ between BRCA1 and BRCA2-mutant ovarian cancer patients.
• Molecular basis for differential clinical profiles remains unclear.

Purpose of the Study:

• Identify molecular pathways differentially regulated by BRCA1 and BRCA2 loss in ovarian cancer.
• Elucidate the role of the Wnt/β-catenin pathway in BRCA-mutant ovarian cancer.

Main Methods:

• Transcriptomic and pathway analyses of BRCA1-mutant, BRCA2-mutant, and wild-type ovarian tumors.
• Wnt3A stimulation experiments in mouse ovarian cancer cell lines (BRCA1/2 wild-type, BRCA1-null, BRCA2-null).
• Analysis of Wnt/β-catenin signaling components, including Axin2, β-catenin, and GSK3β.

Main Results:

• Differential regulation of the Wnt/β-catenin pathway observed between BRCA1/2 mutation statuses.
• BRCA1-null cells showed preferential noncanonical Wnt/β-catenin signaling.
• BRCA2-null cells exhibited unique Wnt3A response with Axin2 upregulation and enhanced β-catenin stability.
• BRCA2-null cells displayed increased inhibitory GSK3β phosphorylation.

Conclusions:

• BRCA1 and BRCA2 mutations differentially regulate the Wnt/β-catenin pathway in ovarian cancer.
• Findings provide molecular insights into differential clinical outcomes for BRCA-mutant ovarian cancer.
• Understanding these pathways may lead to novel therapeutic strategies improving patient survival.